Vertex Pharmaceuticals Researchers Report Three-Dimensional Structure Of Hepatitis C Helicase Enzyme; Report In Structure

Cambridge, MA, January 15, 1998 -- Researchers from Vertex Pharmaceuticals Incorporated have solved the three-dimensional atomic structure of the hepatitis C virus NS3 helicase, an enzyme that plays a key role in viral replication. The achievement is described in a paper, "Hepatitis C Virus NS3 RNA Helicase Domain with a Bound Oligonucleotide: The Crystal Structure Provides Insights into the Mode of Unwinding," published in the January 15, 1998 issue of the journal Structure. The publication follows the presentation of the helicase structure at the Second International Conference on Therapies for Viral Hepatitis in Kona, Hawaii, in December 1997. Vertex is using the structural information to design hepatitis C helicase inhibitors as new antiviral drugs to treat hepatitis C virus (HCV) infection.

"This paper presents for the first time detailed information on the critical interaction between the hepatitis C helicase and viral RNA," said Dr. Joseph L. Kim, Vertex crystallographer and an author of the Structure paper. "The nucleic acid binding site of the helicase enzyme, as well as the previously described nucleoside triphosphate (NTP) binding site, are attractive targets for disrupting this interaction. These two targets, which comprise the active sites of the helicase enzyme, are a focus of our ongoing drug design efforts."

Helicases are enzymes distinguished by their ability to unwind regions of double-stranded RNA or DNA, in preparation for replication or transcription of genetic information. In the case of hepatitis C, the NS3 helicase functions to unwind double-stranded viral RNA complexes. The resulting RNA strands then serve as templates for the synthesis of more RNA or for translation into protein. Alternately, the new RNA may be packaged into new virus particles, which are released from cells to propagate infection.

Vertex scientists determined the three-dimensional structure of h

Contact: Michael Partridge
(617) 577-6108
Vertex Pharmaceuticals

Page: 1 2 3 4

Related biology news :

1. Research Findings Suggest Potent, Broad-Spectrum Antiviral Activity For Vertexs Investigational IMPDH Inhibitor VX-497
2. Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM
3. Vertex Researchers Report Three-Dimensional Atomic Structure Of JNK3 Enzyme; Report In Structure
4. Vertex Pharmaceuticals/Yale Research Team Uses Gene Knockout Mice To Establish Role Of Caspase-9 In Neuronal Cell Death Pathway
5. Warren Pharmaceuticals publishes results of preclinical evaluation
6. Cyclis Pharmaceuticals reports studies defining new mechanism for potential cancer therapies
7. Final results of the two Zevalin pivotal trials in radioimmunotherapy for B cell Non-Hodgkins Lymphoma announced by IDEC Pharmaceuticals
8. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
9. Idun Pharmaceuticals Identifies Cell Type And Molecular Pathway Involved In TransplantationRelated Liver Damage
10. Cubist Pharmaceuticals Describes New VITA™ Technology For Enabling Genomics For Drug Discovery
11. Scientists At The Scripps Research Institute And R.W. Johnson Pharmaceuticals Develop New Antibacterial Agents

Post Your Comments:

(Date:8/23/2018)... FREDERICK, Md. (PRWEB) , ... August 22, 2018 ... ... the pending release of LimitLIS® 4.0, the latest version of its rapidly growing ... toxicology labs, LimitLIS® Toxicology Edition, as well as the company’s triple digit growth ...
(Date:8/21/2018)... Wis. (PRWEB) , ... August 21, 2018 , ... ... high throughput screening (HTS) solutions, Bellbrook Labs is dedicated to offering customers a ... biochemical assays, visitors will find a seamless transition between products, with relevant details ...
(Date:8/17/2018)... ... 16, 2018 , ... Cryo-Cell International, Inc. (OTC:QB Markets Group ... and store stem cells in 1992, announced that Arthur Ellis, JD, Board President ... and Managing Partner IsZo Capital, have joined the Company’s Board of Directors. , ...
Breaking Biology News(10 mins):
(Date:9/13/2018)... ... 13, 2018 , ... Asymmetrex’s director, James L. Sherley, M.D., Ph.D., ... medicine, if we didn’t have the means to measure the number of drug molecules ... “Nowhere! And that is what’s holding up progress in stem cell medicine.” , “Can ...
(Date:9/7/2018)... ... September 05, 2018 , ... Now available on live stream, the NanoScientific ... Sept. 19, 2018. With a panel of industry leaders from Harvard, Cornell, RPI, IBM, ... industry insights from experts in the field. Register today to be a part ...
(Date:9/1/2018)... ... August 31, 2018 , ... Rudina Thanasi, ... of a proprietary biofield energy treated nutraceutical supplement used in combating inflammation and ... response and blood, as well as, organ-specific inflammation. The reported data is as ...
(Date:8/29/2018)... ... August 28, 2018 , ... ... contact lenses, has been ranked in 1138th place on the 27th annual Inc. ... , The list represents the most successful companies within the American economy’s most ...
Breaking Biology Technology:
Cached News: